Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QEV-817 (Hydrocodone + Doxapram) PK and Safety in Healthy Volunteers
NCT06585163Phase 1Completed
- Sponsor
- Quivive Pharma
- Start
- Aug 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydrocodone and doxapram (2 arms), sponsored by Quivive Pharma. Primary endpoint: Number of Participants With Abnormal Laboratory Assessments, 12-Lead Electrocardiogram (ECG), and Vital Signs. Started Aug 2025; status: completed.
02
Drugs
hydrocodonedoxapram
Beyond the preview
Go deeper on NCT06585163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585163.